The Tufts Clinical and Translational Science Institute (CTSI) and Tufts University today announced they are the recipients of four supplemental grant awards from the National Institutes of Health. These new awards, totaling approximately $1.73 million, are supplements to the original Clinical and Translational Science Award (CTSA) grant, UL1 RR025752 that Tufts University received in 2008 from the National Center for Research Resources.
"Community Engagement Research" is a two-year project that will expand the scope of Tufts CTSI's current community engagement program by enhancing the ability of community partners to participate more effectively in the development of research plans and outcomes. Begun in September 2009, the project has already established an alliance between the Tufts CTSI, the Harvard Clinical and Translational Science Center, and two pivotal community partners, the Center for Community Health Education, Research, and Service (CCHERS) and the Immigrant Service Providers Group/Health (ISG/H). This alliance is creating a curriculum and evaluation for a self-study and face-to-face program entitled "Fostering Community Partners in Translational Research (FCPTR)" that will target community agencies and health centers. The Program Director is Laurel Leslie, MD, MPH, Associate Professor of Medicine at Tufts University School of Medicine.
"Improving BPD Predictors and Outcomes for Clinical Trials" builds on prior landmark research that identified a constellation of signs and symptoms in high risk newborns to accurately define bronchopulmonary dysplasia (BPD) and predict the subsequent development of chronic respiratory morbidity (CRM) later in childhood and adolescence. While treatment with recombinant human superoxide dismutase to premature newborns has been proven to have a 55% reduction in CRM compared to placebo controls, current definitions of BPD may be unreliable predictors of CRM and a more robust reduction in CRM is needed. Superoxide dismutase is an enzyme that converts superoxide radicals (highly reactive oxygen molecules produced during metabolism and capable of damaging body tissues) into less toxic agents. This one-year study is a prospective, longitudinal, observational study in 85 preterm infants 24-29 weeks gestation. The Program Director is Jonathan Davis, MD, Chief of Newborn Medicine, The Floating Hospital for Children at Tufts Medical Center, Program Director at the Clinical and Translational Research Center, and Professor of Pediatrics, Tufts University School of Medicine. Partners in this study include Brigham and Women's Hospital (Harvard University), Beth Israel Hospital (Harvard University), Nationwide Children's Hospital (Ohio State), and King's College in London.
"Searching for Persistence of Infection in Lyme Disease" is a highly innovative Bench-to- Bedside research project that could have an extraordinarily significant impact on the field of Lyme disease. Although antibiotic therapy is clinically effective in treating the symptoms of Lyme disease for most patients early in the course of disease, a significant number of patients who receive therapy report persistent symptoms. A range of theories have been proposed for why this occurs. Moreover, commonly available tests for human Lyme disease are not able to determine persistent infection after antibiotic therapy. Program Director, Linden Hu, MD (Associate Professor of Medicine, Tufts University School of Medicine and Associate Professor of Microbiology, Sackler School of Biomedical Graduate Sciences) has begun an unconventional study examining whether xenodiagnosis (the feeding of uninfected Ixodes ticks on infected animals) can be used to determine when persistent infection occurs in humans. Xenodiagnosis has been used for other difficult to diagnose diseases such as Chagas disease and can sometimes definitively identify the presence of an organism in animals where other techniques cannot. Whether xenodiagnosis is effective in humans is unknown. This two-year project seeks to test the utility of xenodiagnosis for identifying persistence of B. burgdorferi, the spirochetal bacteria that cause Lyme disease, after antibiotic treatment of the disease. Dr. Linden's team will test subjects with elevated C6 antibody levels or persistent symptoms after antibiotic therapy and patients with Lyme arthritis. Evidence that B. burgdorferi can be identified by xenodiagnosis after antibiotic therapy in subjects with continued symptoms would significantly change the current paradigm for potential mechanisms of disease and provide researchers and clinicians with a novel tool for identifying patients with persistent infection.
Tufts CTSI currently has a Pilot Studies Program that funds new interdisciplinary research teams, seeds novel ideas, and provides the means to acquire necessary preliminary data for larger, multi-year grant applications. A new supplemental project, The Pilot Project Mechanism, is led by Susan K. Parsons, MD, MRP, Director, The Health Institute, Institute for Clinical Research and Health Policy Studies and Associate Professor of Medicine and Pediatrics, Tufts University School of Medicine, and Amy Yee, PhD, Professor of Biochemistry, Sackler School of Biomedical Graduate Sciences. This two-year project expands the current program to influence research not just within the Tufts enterprise, but also throughout the Commonwealth of Massachusetts and into New England via Tufts CTSI's forty-three collaborating partners by soliciting interinstitutional and multidisciplinary applications. Many of the identified programs will hire and support undergraduate and graduate students and postdoctoral fellows, thereby creating jobs throughout New England and also increasing the pipeline for translational researchers.
Education, wealth, and job type shape aging brains and cognitive health